FDA Proposes Rule to Modernize Drug Manufacturing Registration

A proposed rule would streamline registration for advanced distributed manufacturers, aiming to simplify compliance. It also seeks greater visibility into foreign drug supply sources, which could improve transparency for drug availability and procurement risk.

Analysis

A proposed rule would streamline registration for advanced distributed manufacturers, aiming to simplify compliance. It also seeks greater visibility into foreign drug supply sources, which could improve transparency for drug availability and procurement risk.